Emerging Therapies in Metastatic Breast Cancer

Panelists: William J. Gradishar, MD, Northwestern;Joyce O’Shaughnessy, MD, Texas Oncology;
Christy A. Russell, MD, USC Norris; Debu Tripathy, MD, USC Norris;
Linda Vahdat, MD, Weill Cornell Medical College
Published Online: Thursday, November 29, 2012
For High-Definition, Click
Novel and emerging therapies are currently being investigated to treat patients with metastatic and triple-negative breast cancer. These trials are examining new approaches to antiangiogenic therapy, PARP inhibitors, and the introduction of immunoconjugates.

Several antiangiogenic therapies are currently being investigated for patients with breast cancer, including bevacizumab, sorafenib, and tivozanib.

Joyce A. O’Shaughnessy, MD, describes several trials, including the phase III MERiDiAN trial that is investigating bevacizumab in patients stratified by plasma VEGF-A levels. This trial hopes to discover a predictive biomarker for the use of bevacizumab. In general, patients with triple-negative breast cancer (TNBC) seem to have higher levels of plasma VEGF-A, suggesting a higher response to bevacizumab.

Several trials are examining combination strategies with sorafenib, an antiangiogenic therapy that inhibits VEGFR, PDGFR, and Raf kinases. William J. Gradishar, MD, believes the most promising is the phase III RESILIENCE trial that is comparing capecitabine plus sorafenib to capecitabine and placebo for patients with advanced breast cancer.

In addition to antiangiogenic therapies, several PARP inhibitors and immunoconjugates are also under investigation. Patients with BRCA mutations seem to be particularly sensitive to PARP inhibitors, even when given as a monotherapy, Gradishar points out. O'Shaughnessy adds that PARP inhibitors may even be effective more generically in patients with double-strand DNA repair problems and not exclusively BRCA mutations.

In TNBC, the main concern remains finding druggable targets. Linda T. Vahdat, MD, believes the immunoconjugate glembatumumab vedotin (CDX-001) shows potential in TNBC by targeting GPNMB.
View More From This Discussion
Episode 1 Improving the Management of Metastatic Breast Cancer, Part I
Episode 2 Management of Metastatic Breast Cancer, Part II
Episode 3 Chemotherapy in Advanced Breast Cancer
Episode 4 Emerging Therapies in Metastatic Breast Cancer
Episode 5 Managing Skeletal-Related Events in Breast Cancer, Part I
Episode 6 Managing Skeletal-Related Events in Breast Cancer, Part II
Episode 7 Molecular and Personalized Medicine in Breast Cancer
Expert Panelists
Debu Tripathy

Debu Tripathy, MD

Co-Leader, Women's Cancer Program
USC Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, California

William J. Gradishar, MD

Director, Maggie Daley Center
for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Joyce A. O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Dallas, Texas

Christy A. Russell, MD

Co-Director, USC Norris Breast Center
USC Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, California

Linda T. Vahdat, MD

Director, Breast Cancer Research Program
Head, Solid Tumor Service
Weill Cornell Medical College
New York, New York
Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading